Td Asset Management Inc Bicycle Therapeutics PLC Transaction History

Td Asset Management Inc

$102 Billion
Q1 2025

A detailed history of Td Asset Management Inc transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Td Asset Management Inc holds 193,092 shares of BCYC stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

193,092

Previous 216,016 10.61%

Holding current value

$1.64 Million

Previous $3.02 Million 45.8%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	SELL	$8.49 - $15.16 $194,624 - $347,527	-22,924 Reduced 10.61%	193,092 $1.64 Million
Q4 2024 Feb 11, 2025	SELL	$13.81 - $27.5 $74,574 - $148,500	-5,400 Reduced 2.44%	216,016 $3.02 Million
Q3 2024 Nov 01, 2024	BUY	$19.58 - $27.24 $2.43 Million - $3.38 Million	124,230 Added 127.83%	221,416 $5.02 Million
Q2 2024 Aug 02, 2024	BUY	$20.02 - $24.69 $844,844 - $1.04 Million	42,200 Added 76.75%	97,186 $1.97 Million
Q1 2024 May 08, 2024	BUY	$16.75 - $26.1 $331,650 - $516,780	19,800 Added 56.27%	54,986 $1.37 Million
Q4 2023 Feb 12, 2024	SELL	$13.29 - $22.2 $619,314 - $1.03 Million	-46,600 Reduced 56.98%	35,186 $636,000
Q3 2023 Oct 27, 2023	BUY	$19.9 - $26.25 $1.16 Million - $1.53 Million	58,200 Added 246.76%	81,786 $1.64 Million
Q4 2022 Feb 06, 2023	BUY	$20.37 - $32.9 $162,960 - $263,200	8,000 Added 51.33%	23,586 $698,000
Q2 2022 Aug 04, 2022	SELL	$12.95 - $46.99 $174,825 - $634,365	-13,500 Reduced 46.41%	15,586 $262,000
Q1 2022 May 10, 2022	SELL	$40.12 - $59.5 $100,300 - $148,750	-2,500 Reduced 7.91%	29,086 $1.28 Million
Q4 2021 Feb 10, 2022	BUY	$41.7 - $61.14 $1.32 Million - $1.93 Million	31,586 New	31,586 $1.92 Million

Others Institutions Holding BCYC

# of Institutions

101

Shares Held

42.8M

Call Options Held

15.6K

Put Options Held

27.7K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $252M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Bicycle Therapeutics PLC Transaction History